Oral Azelaic Acid Ester Decreases Markers of Insulin Resistance in Overweight Human Male Subjects.

Abstract

BACKGROUND/AIM:

Insulin resistance (IR) is linked to increased risk of cardiovascular disease and cancer. We examined safety and efficacy of the natural product diethyl azelate (DEA) in overweight males with a varying degree of IR.

PATIENTS AND METHODS:

Seventeen subjects [age 18-42, hemoglobin A1c (A1c) of 5.2-6.2%] received orally 1 mg/kg DEA daily for 21 days. Blood plasma glucose, insulin and lipid levels were assessed before and after treatment.

RESULTS:

DEA was well tolerated without hypoglycemia or adverse effects except transient diarrhea (n=1). DEA significantly reduced fasting glucose by 6.06 mg/dl (n=8) and insulin by 37.8% (n=8) in subjects with IR and/or A1c ≥5.6%. Furthermore, it improved cholesterol/HDL, LDL/HDL, and non-cholesterol HDL/HDL by 5.4, 6.5, and 6.6%, respectively in all subjects, and by 8.0, 9.8, and 9.8%, respectively in 9 subjects with A1c ≥5.6%.

CONCLUSION:

DEA efficacy correlates with the degree of IR. DEA holds promise as a novel treatment for the management of IR.

• Authors: Robert T Streeper, Christopher Louden, Elzbieta Izbicka
• Journal: In vivo (Athens, Greece) (In Vivo) 2020 May-Jun Vol. 34 Issue 3 Pg. 1173-1186 ISSN: 1791-7549 [Electronic] Greece
• PMID: 32354907 (Publication Type: Journal Article)
• Copyright: Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Chemical References

• Biomarkers
• Blood Glucose
• Dicarboxylic Acids
• Esters
• Insulin
• azelaic acid

Topics

• Administration, Oral
• Biomarkers
• Blood Glucose
• Dicarboxylic Acids (administration & dosage, chemistry)
• Esters
• Gas Chromatography-Mass Spectrometry
• Humans
• Insulin (blood)
• Insulin Resistance
• Lipid Metabolism
• Male
• Overweight (blood, drug therapy, etiology, metabolism)
• Sex Factors